Published in Eur J Nucl Med on May 01, 2000
Positron detection for the intraoperative localisation of cancer deposits. Eur J Nucl Med Mol Imaging (2007) 1.95
Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging (2008) 1.76
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol (2016) 1.32
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging (2003) 1.23
O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging (2005) 1.20
O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging (2005) 1.14
Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging (2012) 1.12
Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.11
Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging (2003) 1.06
18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging (2003) 1.05
Brain tumors. Semin Nucl Med (2012) 1.05
Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging (2014) 1.04
[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol (2008) 1.04
Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol (2010) 1.04
Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance? Eur J Nucl Med Mol Imaging (2010) 1.03
MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging (2012) 0.99
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol (2015) 0.99
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol (2015) 0.97
Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging (2003) 0.97
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging (2006) 0.92
Serial O-(2-[(18)F]fluoroethyl)-L: -tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging (2006) 0.90
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
[(18)F]FET-PET Imaging for Treatment and Response Monitoring of Radiation Therapy in Malignant Glioma Patients - A Review. Front Oncol (2013) 0.89
18F-AFETP, 18F-FET, and 18F-FDG imaging of mouse DBT gliomas. J Nucl Med (2013) 0.89
Highly cited German research contributions to the fields of radiation oncology, biology, and physics: focus on collaboration and diversity. Strahlenther Onkol (2012) 0.89
Radiosyntheses using fluorine-18: the art and science of late stage fluorination. Curr Top Med Chem (2014) 0.88
Beyond FDG: novel PET tracers for cancer imaging. Cancer Imaging (2003) 0.88
Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. Neuro Oncol (2013) 0.86
18F-FET-PET-based dose painting by numbers with protons. Strahlenther Onkol (2010) 0.86
18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging (2009) 0.85
Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging (2009) 0.84
Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat. Eur J Nucl Med Mol Imaging (2006) 0.84
Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma. Eur Radiol (2013) 0.83
Diagnostics of cerebral gliomas with radiolabeled amino acids. Dtsch Arztebl Int (2008) 0.82
Intra-individual comparison of p-[123I]-iodo-L-phenylalanine and L-3-[123I]-iodo-alpha-methyl-tyrosine for SPECT imaging of gliomas. Eur J Nucl Med Mol Imaging (2007) 0.81
Imaging biomarkers in primary brain tumours. Eur J Nucl Med Mol Imaging (2014) 0.80
Radiosynthesis and biological evaluation of N-[18F]labeled glutamic acid as a tumor metabolic imaging tracer. PLoS One (2014) 0.80
Validation of brain tumour imaging with p-[123I]iodo-L-phenylalanine and SPECT. Eur J Nucl Med Mol Imaging (2005) 0.80
Novel Approaches to Imaging Tumor Metabolism. Cancer J (2015) 0.80
(18)F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. Childs Nerv Syst (2014) 0.79
3-O-methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging (2003) 0.79
Radiosynthesis and biological evaluation of alpha-[F-18]fluoromethyl phenylalanine for brain tumor imaging. Nucl Med Biol (2013) 0.78
The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II. Int J Mol Imaging (2011) 0.78
Imaging tumor metabolism using positron emission tomography. Cancer J (2015) 0.78
Contribution of (18)F-Fluoro-ethyl-tyrosine Positron Emission Tomography to Target Volume Delineation in Stereotactic Radiotherapy of Malignant Cranial Base Tumours: First Clinical Experience. Int J Mol Imaging (2012) 0.78
The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology. ISRN Oncol (2012) 0.77
Tryptophan PET predicts spatial and temporal patterns of post-treatment glioblastoma progression detected by contrast-enhanced MRI. J Neurooncol (2015) 0.77
Synthesis and Biological Evaluation of (S)-Amino-2-methyl-4-[(76)Br]bromo-3-(E)-butenoic Acid (BrVAIB) for Brain Tumor Imaging. J Med Chem (2015) 0.77
The impact of 18 F-FET PET-CT on target definition in image-guided stereotactic radiotherapy in patients with skull base lesions. Cancer Imaging (2014) 0.76
Newer positron emission tomography radiopharmaceuticals for radiotherapy planning: an overview. Ann Transl Med (2016) 0.76
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of gliomas located in the brainstem and spinal cord. Neuro Oncol (2016) 0.75
Targeting Amino Acid Metabolism for Molecular Imaging of Inflammation Early After Myocardial Infarction. Theranostics (2016) 0.75
A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model. PLoS One (2016) 0.75
PET tracer development--a tale of mice and men. Cancer Imaging (2006) 0.75
Radiotherapy to volumes defined by metabolic imaging in gliomas: time to abandon monstrous margins? Ann Transl Med (2016) 0.75
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET. EJNMMI Res (2017) 0.75
Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas. PLoS One (2016) 0.75
The Sum of Tumour-to-Brain Ratios Improves the Accuracy of Diagnosing Gliomas Using 18F-FET PET. PLoS One (2015) 0.75
Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging (2016) 0.75
[18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One (2017) 0.75
Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med (1986) 4.69
Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med (2001) 3.39
Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med (1999) 3.20
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol (2001) 2.91
Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol (1994) 2.78
Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med (1986) 2.63
Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol (2000) 2.58
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol (2000) 2.28
Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet (1999) 2.21
Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol (1992) 2.18
Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET. J Nucl Med (1991) 2.18
Evaluation of the novel myocardial perfusion positron-emission tomography tracer 18F-BMS-747158-02: comparison to 13N-ammonia and validation with microspheres in a pig model. Circulation (2009) 2.15
Informatics and medicine--from molecules to populations. Methods Inf Med (2008) 2.13
Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med (2001) 2.12
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med (1991) 2.07
Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol (1990) 2.07
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg (2001) 2.04
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology (2009) 1.99
Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med (1995) 1.95
Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol (1999) 1.86
Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain (2001) 1.83
Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol (1990) 1.73
Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging (2007) 1.70
The relationship between myocardial retention of technetium-99m teboroxime and myocardial blood flow. J Am Coll Cardiol (1992) 1.68
Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol (1997) 1.68
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med (1999) 1.63
Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images. Eur J Nucl Med (1997) 1.61
Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A (2009) 1.60
Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys (1999) 1.51
Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol (1989) 1.51
Quantitative evaluation of regional substrate metabolism in the human heart by positron emission tomography. J Am Coll Cardiol (1991) 1.48
Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J (2001) 1.47
The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging (2007) 1.46
Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med (1991) 1.46
Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically? Eur J Nucl Med (2000) 1.45
Region-specific encoding of sensory and affective components of pain in the human brain: a positron emission tomography correlation analysis. Ann Neurol (1999) 1.43
Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer (2008) 1.42
A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev (2000) 1.42
Focal metabolic activation in the predominant left auditory cortex in patients suffering from tinnitus: a PET study with [18F]deoxyglucose. ORL J Otorhinolaryngol Relat Spec (1997) 1.42
Noninvasive assessment of regional cardiac adenosine using positron emission tomography. J Nucl Med (1992) 1.41
Determination of extent and location of coronary artery disease in patients without prior myocardial infarction by thallium-201 tomography with pharmacologic stress. J Nucl Med (1992) 1.41
Comparison of technetium-99m sestamibi and thallium-201 retention characteristics in canine myocardium. J Am Coll Cardiol (1992) 1.41
A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol (1996) 1.40
Correlation of work structure and job satisfaction among Israeli family physicians. Isr Med Assoc J (1999) 1.40
An automated analysis program for the evaluation of cardiac PET studies: initial results in the detection and localization of coronary artery disease using nitrogen-13-ammonia. J Nucl Med (1993) 1.39
Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging (2006) 1.39
Early recovery of coronary flow reserve after stent implantation as assessed by positron emission tomography. J Am Coll Cardiol (1999) 1.38
Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys (2001) 1.38
Characterization of translocation contact sites involved in the import of mitochondrial proteins. J Cell Biol (1987) 1.37
Synthesis of n.c.a. carbon-11 labelled clozapine and its major metabolite clozapine-N-oxide and comparison of their biodistribution in mice. Nucl Med Biol (1994) 1.37
Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med (1993) 1.36
Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology (2005) 1.33
Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging (2012) 1.33
A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group. Circulation (1992) 1.32
Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood (1998) 1.32
Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med (1989) 1.30
Cardiac sympathetic dysinnervation in diabetes: implications for enhanced cardiovascular risk. Circulation (1998) 1.29
Carbon-11-acetate PET imaging in renal disease. J Nucl Med (1995) 1.28
Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr (1995) 1.26
Synthesis and biological evaluation of a (99m)Tc-labelled cyclic RGD peptide for imaging the alphavbeta3 expression. Nuklearmedizin (2004) 1.25
Uptake of radiolabeled 2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil in cardiac cells after adenoviral transfer of the herpesvirus thymidine kinase gene: the cellular basis for cardiac gene imaging. Circulation (2000) 1.22
Inter-crystal scatter in a dual layer, high resolution LSO-APD positron emission tomograph. Phys Med Biol (2003) 1.22
Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation (2000) 1.20
Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst (1996) 1.19
Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med (1997) 1.18
Early detection of abnormal coronary flow reserve in asymptomatic men at high risk for coronary artery disease using positron emission tomography. Circulation (1994) 1.18
Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2000) 1.17
Comparison of rubidium-82 positron emission tomography and thallium-201 SPECT imaging for detection of coronary artery disease. Am J Cardiol (1991) 1.17
Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain (2001) 1.16
Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the rectal mucosa. Strahlenther Onkol (1998) 1.16
Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med (2001) 1.16
Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med (1999) 1.14
Myocardial blood flow and flow reserve after coronary reimplantation in patients after arterial switch and ross operation. Circulation (2001) 1.13
Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol (1996) 1.13
NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J Biol Chem (2001) 1.12